Ockham has completed the acquisition of Nexus Oncology. The combined company will operate under the name Ockham and will be led by James V. Baker, Ockham’s chief executive officer, and a joint management team. Nexus Oncology will run as a separate unit under Clare Wareing, founder of Nexus. She will serve as chief scientific officer. With the addition of Nexus, Ockham now has approximately 300 employees across 12 countries. The merger enhances Ockham’s global scale, as well as oncology-specific...